By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – Investment firm Rodman & Renshaw has upgraded Sequenom's stock to "Market Perform" from "Market Underperform" following yesterday's publication by the San Diego-based firm of results on its non-invasive fetal trisomy 21 test.
Registering provides access to this and other free content.
Already have an account?Login Now.
In Science this week: gene linked to expansion of the human neocortex, and more.
The National Institute of General Medical Sciences director says changes the agency made have allow it to boost success rates.
Ancient DNA indicates Stone Age, hunter-gather inhabitants of Britain imported wheat.
Joel Achenbach explores at National Geographic why people find science difficult to believe.